Entry Point Capital, LLC Xenon Pharmaceuticals Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 26 shares of XENE stock, worth $1,189. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26
Previous 4,541
99.43%
Holding current value
$1,189
Previous $195 Million
99.48%
% of portfolio
0.0%
Previous 0.18%
Shares
2 transactions
Others Institutions Holding XENE
# of Institutions
222Shares Held
69.7MCall Options Held
59.7KPut Options Held
60.7K-
Avoro Capital Advisors LLC New York, NY5.67MShares$259 Million3.02% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.42MShares$202 Million1.86% of portfolio
-
Wellington Management Group LLP Boston, MA3.83MShares$175 Million0.03% of portfolio
-
Commodore Capital LP New York, NY2.75MShares$126 Million9.63% of portfolio
-
Capital World Investors Los Angeles, CA2.68MShares$123 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.85B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...